Psychedelic DMT for Alcohol Use Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 1 trial gives a single infusion of DMT alongside a short course of psychotherapy to adults with Alcohol Use Disorder. Participants are randomized to receive one of several infusion regimens (including a 0.3 mg/kg/min DMT infusion, a lower-dose/control infusion, or diphenhydramine plus saline) under double-blind conditions. The primary goals are to measure safety and tolerability and to see if a single DMT session reduces alcohol consumption in a laboratory drinking session the next day and over an 8-week follow-up. All participants must be medically stable, meet DSM-5 criteria for AUD, and attend in-person visits at the Connecticut Mental Health Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnosis of Alcohol Use Disorder
* Medically healthy
* Ability to provide consent

Exclusion Criteria:

* Unstable medical conditions

Where it's running

• Connecticut Mental Health Center
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Anahita Bassir Nia, MD — Yale University
• Study coordinator: Angelina Contreras
• Email: angelina.contreras@yale.edu
• Phone: (203) 974-7525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Body-focused mindfulness added to inpatient alcohol use disorder treatment

  This trial tests whether a body-focused mindfulness program can help people with alcohol use disorder feel more connected to their bodies and reduce cravings while in inpatient care.

  Recruiting Medical University of Warsaw · Warsaw, Mazovian · NCT07706660

• Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder

  This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.

  Recruiting Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07825818

• Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD

  A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07824089

• Do beverage cues drive craving in adults with AUD

  In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07788716

• Semaglutide for Alcohol Use Disorder and Obesity: Testing 1.0 mg and 2.0 mg vs Placebo

  We’re testing two doses of semaglutide to see if they reduce alcohol craving and use in adults with alcohol use disorder and obesity compared with placebo.

  Recruiting at 2 sites Phase 1 Yale University · New Haven, Connecticut and 1 other locations · NCT07772960

• TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder

  A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07735585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.